{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:00:50Z","timestamp":1791806450473,"version":"4.3.4"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>A new formulation of posaconazole (PCZ), delayed\u2010release tablets (PCZ\u2010tab), increases PCZ bioavailability and plasma trough concentrations (C<jats:sub>min<\/jats:sub>) over those achieved with an oral suspension (PCZ\u2010susp). PCZ is an inhibitor of cytochrome P450 3A4 and P\u2010glycoprotein. We therefore investigated the impact of PCZ\u2010tab treatment on blood C<jats:sub>min<\/jats:sub> and doses of tacrolimus (TAC) and everolimus (EVR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Eighteen lung transplant patients receiving TAC (<jats:italic>n<\/jats:italic> = 13) or TAC + EVR (<jats:italic>n<\/jats:italic> = 5) between June 2015 and March 2016 were retrospectively included. Ten of these patients received both PCZ\u2010tab and PCZ\u2010susp (i.e. switched patients); the other 8 received only PCZ\u2010tab. Plasma C<jats:sub>min<\/jats:sub> of PCZ (<jats:italic>n<\/jats:italic> = 64), blood C<jats:sub>min<\/jats:sub> of TAC (<jats:italic>n<\/jats:italic> = 299) and EVR (<jats:italic>n<\/jats:italic> = 80) were determined during routine therapeutic drug monitoring by liquid chromatography\u2013tandem mass spectrometry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>PCZ C<jats:sub>min<\/jats:sub> on PCZ\u2010tab treatment (<jats:italic>n<\/jats:italic> = 48) was 2.5 times higher than that on PCZ\u2010susp therapy (<jats:italic>n<\/jats:italic> = 16), for both PCZ patients (<jats:italic>P<\/jats:italic> &lt; .0001) and for switched patients (<jats:italic>P<\/jats:italic> = .003). PCZ initiation, regardless of galenic form, increased TAC and EVR C<jats:sub>min<\/jats:sub> adjusted for dose (D), 3\u2010fold and 3.5\u2010fold, respectively (<jats:italic>P &lt;<\/jats:italic> .0001 for both). PCZ\u2010tab treatment was associated with a higher TAC C<jats:sub>min<\/jats:sub>\/D (PCZ\u2010tab <jats:italic>vs<\/jats:italic> PCZ\u2010susp: 0.004 \u00b1 0.004 L<jats:sup>\u22121<\/jats:sup> <jats:italic>vs<\/jats:italic> 0.009 \u00b1 0.006 L<jats:sup>\u22121<\/jats:sup>, <jats:italic>P &lt;<\/jats:italic> .0001) and lower TAC daily dose than PCZ\u2010susp (PCZ\u2010tab <jats:italic>vs<\/jats:italic> PCZ\u2010susp: 1.08 \u00b1 0.92 <jats:italic>vs<\/jats:italic> 2.32 \u00b1 1.62 mg d<jats:sup>\u20131<\/jats:sup>, <jats:italic>P &lt;<\/jats:italic> .0001). EVR C<jats:sub>min<\/jats:sub>\/D was higher and EVR dose tended to be lower on PCZ\u2010tab than on PCZ\u2010susp.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The greater PCZ exposure achieved during PCZ\u2010tab treatment increased drug\u2013drug interactions with TAC and EVR, resulting in greater exposure, potentially exposing patients to higher risks of adverse effects.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.14398","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T06:53:40Z","timestamp":1590821620000},"page":"427-435","source":"Crossref","is-referenced-by-count":11,"title":["Tablets or oral suspension for posaconazole in lung transplant recipients? Consequences for trough concentrations of tacrolimus and everolimus"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7708-9777","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Chanoine","sequence":"first","affiliation":[{"name":"Universit\u00e9 Grenoble Alpes, Facult\u00e9 de Pharmacie  Grenoble France"},{"name":"Institute for Advanced Biosciences UGA \u2013 Inserm U 1209 \u2013 CNRS UMR 5309  Grenoble France"},{"name":"P\u00f4le Pharmacie, CHU Grenoble Alpes  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Gautier\u2010Veyret","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Grenoble Alpes, HP2  Grenoble France"},{"name":"INSERM U1042  Grenoble France"},{"name":"Laboratoire de Pharmacologie Pharmacog\u00e9n\u00e9tique et Toxicologie, CHU Grenoble Alpes  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Pluchart","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Grenoble Alpes, Facult\u00e9 de Pharmacie  Grenoble France"},{"name":"P\u00f4le Pharmacie, CHU Grenoble Alpes  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Tonini","sequence":"additional","affiliation":[{"name":"Laboratoire de Pharmacologie Pharmacog\u00e9n\u00e9tique et Toxicologie, CHU Grenoble Alpes  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Fonrose","sequence":"additional","affiliation":[{"name":"Laboratoire de Pharmacologie Pharmacog\u00e9n\u00e9tique et Toxicologie, CHU Grenoble Alpes  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Claustre","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Grenoble Alpes, Facult\u00e9 de M\u00e9decine  Grenoble France"},{"name":"Service hospitalo\u2010universitaire de Pneumologie\u2010Physiologie, CHU Grenoble Alpes  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierrick","family":"Bedouch","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Grenoble Alpes, Facult\u00e9 de Pharmacie  Grenoble France"},{"name":"P\u00f4le Pharmacie, CHU Grenoble Alpes  Grenoble France"},{"name":"CNRS, TIMC\u2010IMAG UMR5525\/ThEMAS, Univ Grenoble Alpes  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4643-6323","authenticated-orcid":false,"given":"Fran\u00e7oise","family":"Stanke\u2010Labesque","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Grenoble Alpes, HP2  Grenoble France"},{"name":"INSERM U1042  Grenoble France"},{"name":"Laboratoire de Pharmacologie Pharmacog\u00e9n\u00e9tique et Toxicologie, CHU Grenoble Alpes  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,6,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04035-14"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00581-15"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv380"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2016.01.007"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12452"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000371"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13300"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx440"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12724"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02061-17"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.8.842"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2012.12.028"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318198d092"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200410000-00007"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12339"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00496-15"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01166-17"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12751"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14232"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03680.x"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02931-15"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2016.05.001"},{"key":"e_1_2_10_24_1","unstructured":"Summary of Product Characteristics NOXAFIL.2013.1\u201312."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200929070-00006"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.152900"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw444"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.14398","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14398","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14398","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T08:42:51Z","timestamp":1693212171000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,22]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1111\/bcp.14398"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14398","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,22]]}}}